Knight Therapeutics Reports Third Quarter 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Q3 2023 Highlights

Financial Results

Revenues were $81,500, an increase of $9,219 or 13% over the same period in prior year.
Gross margin of $40,182 or 49% compared to $30,401 or 42% in the same period in prior year.
Adjusted EBITDA ¹ was $15,512, an increase of $6,503 or 72% over the same period in prior year.
Adjusted EBITDA per share ¹ of $0.15, an increase of $0.07 or 87% over the same period in prior year.
Net gain on financial assets measured at fair value through profit or loss of $5,562.
Net income was $9,588, compared to $1,591 in the same period in the prior year.
Cash inflow from operations was $15,166, an increase of $3,374 or 29% over the same period in prior year.

Corporate Developments

Launched a NCIB to purchase up to 5,999,524 common shares of the Company over the next 12 months.
Purchased 2,158,091 common shares through Knight's NCIB at an average price of $4.55 for aggregate cash consideration of $9,833.

Products

Submitted marketing authorization for Tavalisse ^® (fostamatinib) in Colombia and Mexico.
Obtained regulatory approval for Minjuvi ^® (tafasitamab) in Brazil.
In-licensed a branded generic molecule in Oncology/Hematology for Brazil.

Subsequent to quarter-end

Obtained CMED pricing approval for Minjuvi ^® in Brazil.
Submitted marketing authorization for Pemazyre ^® (pemigatinib) in Brazil.

"I am excited to announce that for the nine months ended September 30, 2023, we reported record revenues and record adjusted EBITDA of over $254,000 and over $48,000, respectively, which represents a growth of 20% and 19%, respectively, over the same period last year, putting us on track to deliver record 2023 results. In addition, we advanced our product pipeline with the Brazilian pricing approval for Minjuvi ^® which we expect to launch in the second quarter of 2024. We continue to execute on our mission to build a leading Pan-American ex US specialty pharmaceutical company by bringing innovative and branded generic products to our markets," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

¹	_{Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP measures. Refer to section "Non-GAAP measures" and "Reconciliation to adjusted EBITDA" for additional details.}

SELECT FINANCIAL RESULTS REPORTED UNDER IFRS
[In thousands of Canadian dollars]

					Change							Change
	Q3-23		Q3-22		$ ¹	% ²		YTD-23		YTD-22		$ ¹		% ²

Revenues	81,500		72,281		9,219	13	%	254,002		211,908		42,094		20	%
Gross margin	40,182		30,401		9,781	32	%	118,437		101,173		17,264		17	%
Gross margin %	49	%	42	%				47	%	48	%
Operating expenses ⁴	39,252		42,415		3,163	7	%	111,984		111,167		(817	)	1	%
Net income (loss)	9,588		1,591		7,997	503	%	7,491		(14,704	)	22,195		151	%
EBITDA ³	15,512		9,009		6,503	72	%	48,018		40,211		7,807		19	%
Adjusted EBITDA ³	15,512		9,009		6,503	72	%	48,018		40,211		7,807		19	%
Adjusted EBITDA per share ³	0.15		0.08		0.07	87	%	0.46		0.35		0.11		30	%

^₁	_{A positive variance represents a positive impact to net income (loss) and a negative variance represents a negative impact to net income (loss)}
^₂	_{Percentage change is presented in absolute values}
^₃	_{EBITDA, adjusted EBITDA and adjusted EBITDA per share are non-GAAP measures. Refer to section "Non-GAAP measures" for additional details}
^₄	_{Operating expenses include selling and marketing expenses, general and administrative expenses, research and development expenses, amortization of intangible assets and impairment of intangible assets}

SELECT FINANCIAL RESULTS AT CONSTANT CURRENCY
[In thousands of Canadian dollars]

	Q3-23		Q3-22		Variance			YTD-23		YTD-22		Variance
	Excluding impact of IAS 29 ¹
			Constant Currency ¹		$ ²	% ³				Constant Currency ¹		$ ²		% ³

Revenues	81,669		73,358		8,311	11	%	254,736		216,461		38,275		18	%
Gross margin	42,121		35,846		6,275	18	%	123,751		113,345		10,406		9	%
Gross margin %	52	%	49	%				49	%	52	%
Operating expenses ⁴	39,072		40,243		1,171	3	%	111,884		108,047		(3,837	)	4	%
EBITDA ¹	15,512		9,925		5,587	56	%	48,018		43,197		4,821		11	%
Adjusted EBITDA ¹	15,512		9,925		5,587	56	%	48,018		43,197		4,821		11	%
Adjusted EBITDA per share ¹	0.15		0.09		0.06	70	%	0.46		0.38		0.08		21	%

¹	_{Financial results at constant currency, excluding the impact of hyperinflation, EBITDA, adjusted EBITDA and adjusted EBITDA per share are non-GAAP measures. Refer to section "Non-GAAP measures" and "Reconciliation to adjusted EBITDA" for additional details.}
²	_{A positive variance represents a positive impact to net income (loss) and a negative variance represents a negative impact to net income (loss).}
³	_{Percentage change is presented in absolute values.}
⁴	_{Operating expenses include selling and marketing expenses, general and administrative expenses, research and development expenses, amortization of intangible assets and impairment of intangible assets}

SELECT BALANCE SHEET ITEMS
[In thousands of Canadian dollars]

			Change
	09-30-23	12-31-22	$		% ¹

Cash, cash equivalents and marketable securities	153,815	172,674	(18,859	)	11	%
Trade and other receivables	144,841	151,669	(6,828	)	5	%
Inventory	112,447	92,489	19,958		22	%
Financial assets	158,470	176,563	(18,093	)	10	%
Accounts payable and accrued liabilities	83,002	108,730	(25,728	)	24	%
Bank loans	75,364	70,072	5,292		8	%

¹	_{Percentage change is presented in absolute values}

Revenues: For the quarter ended September 30, 2023, excluding the impact of hyperinflation, revenues increased by $12,558 or 18% compared to the same period in prior year. The appreciation of select LATAM currencies led to an increase in revenues of $4,248 in Q3-23 compared to Q3-22. The revenues by therapeutic areas are as follows:

	Excluding impact of IAS 29 ³
			Change
Therapeutic Area	Q3-23	Q3-22	$ ¹	% ²
Oncology/Hematology	31,336	26,271	5,065	19	%
Infectious Diseases	29,195	27,244	1,951	7	%
Other Specialty	21,138	15,596	5,542	36	%
Total	81,669	69,111	12,558	18	%

¹	_{A positive variance represents a positive impact to net income (loss) and a negative variance represents a negative impact to net income (loss)}
²	_{Percentage change is presented in absolute values}
³	_{Revenues excluding the impact of IAS 29 is a non-GAAP measure, refer to section "Non-GAAP measures" for additional details.}

The increase in revenues excluding the impact of hyperinflation is explained by the following:

Oncology/Hematology : The oncology/hematology portfolio grew by approximately $7,300 primarily due to continued growth of key promoted products including Lenvima ^® , Trelstar ^® , Palbocil ^® launched in Argentina in Q1-23 and the assumption of commercial activities of Akynzeo ^® in Brazil, Argentina and Canada in 2022. The increase is offset by a reduction of approximately $2,200 in revenues of our mature and branded generics products due to their lifecycle including the entrance of new competitors.
Infectious Diseases : The increase is driven by our key promoted products, including Cresemba ^® , as well as higher demand of Impavido ^® , offset by the purchasing patterns for certain products. Furthermore, Knight received an order for Ambisome ^® for $4,875 from MOH, which is expected to be delivered in Q4-23 ("Q4-23 MOH Order").
Other Specialty : The increase in the other specialty portfolio is primarily driven by the transition of commercial operations of Exelon ^® from Novartis to Knight. The revenues of Exelon ^® increased by approximately $5,700 in Q3-23 versus Q3-22. In Q3-22, Knight recorded lower revenues of Exelon ^® due to advance purchases of $3,000 in Brazil and Colombia in Q2-22, in connection with the transition of commercial activities. The remainder of the variance is explained by the change in accounting treatment from net profit transfer to revenues with related costs of sales upon the transition as well as timing of purchases from certain customers.

Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22. Excluding the impact of IAS 29, gross margin, as a percentage of revenues, was 52% in Q3-23 and 49% in Q3-22. The increase is driven by the change in product mix.

Selling and marketing ("S&M"): For the quarter ended September 30, 2023, S&M expenses were $11,924, a decrease of $1,532 or 11%, compared to the same period in prior year. Excluding the impact of IAS 29, the decrease is $634 or 5%. There is no significant variance in S&M expenses.

General and administrative ("G&A"): For the quarter ended September 30, 2023, G&A expenses were $11,080, an increase of $664 or 6%, compared to the same period in prior year. Excluding the impact of IAS 29, the increase is $1,902 or 21%, mainly due to an increase in our compensation costs related to Knight's long term incentive plan as well as higher spending on professional and consulting fees.

Research and development ("R&D"): For the quarter ended September 30, 2023, R&D expenses were $4,768, an increase of $548 or 13%, compared to the same period in prior year. Excluding the impact of IAS 29, the increase is $968 or 26%. The increase is driven by an expansion in our product development and medical initiatives.

Amortization of intangible assets: For the quarter ended September 30, 2023, amortization of intangible assets was $11,480, a decrease of $763 or 6% compared to the same period in prior year. There is no significant variance.

Impairment of intangible assets: For the quarter ended September 30, 2023, impairment of intangible assets was nil, compared to an impairment of $2,080 recognized in Q3-22 which represents the write-down of upfront and certain milestones payments made under certain product license agreements as a result of changes in commercial expectations.

Interest income: Interest income is the sum of interest income on financial instruments measured at amortized cost and other interest income. For the quarter ended September 30, 2023, interest income was $3,055, an increase of $593 or 24%, compared to the same period in prior year. The increase is driven by higher interest rates on cash and marketable securities.

Interest expense: For the quarter ended September 30, 2023, interest expenses were $2,603, an increase of $1,124 or 76%, compared to the same period in prior year. The increase is driven by the higher average loan balance resulting from IFC loan which closed in December 2022 and higher variable interest rates, partially offset by principal repayments of Itaú Unibanco Brasil and Bancolombia bank loans.

Adjusted EBITDA: For the quarter ended September 30, 2023, adjusted EBITDA increased by $6,503 or 72%, driven by an increase in gross margin (excluding impact of IAS 29) of $8,324, offset by an increase in operating expenses.

Net income : For the quarter ended September 30, 2023, net income was $9,588 compared to net income of $1,591 for the same period in prior year. The variance mainly resulted from the above-mentioned items and (1) a net gain on the revaluation of financial assets measured at fair value through profit or loss of $5,562 versus a net loss of $5,446 in the same period in prior year mainly driven by realized and unrealized gains and losses in the fair value of financial assets, (2) a foreign exchange loss of $1,317 in Q3-23 mainly driven by unrealized losses due to the appreciation of select LATAM currencies versus a foreign exchange gain of $10,787 in Q3-22 mainly driven by unrealized gains due to the appreciation of the USD and (3) other income of $1,907 in Q3-23 relating to certain fees recognized on strategic loans, as well as a gain on a disposal of a property in Colombia compared to an income of $5,860 in Q3-22 mainly relating to the gain recognized upon execution of a settlement agreement and general release with the former shareholders of GBT.

Cash, cash equivalents and marketable securities : As at September 30, 2023, Knight had $153,815 in cash, cash equivalents and marketable securities, a decrease of $18,859 or 11% as compared to December 31, 2022. The variance is primarily due to cash outflows for certain regulatory and sales milestones on certain products, including Akynzeo ^® and Aloxi ^® from Helsinn, shares repurchased through NCIB and repayment of bank loans, partially offset by cash inflows from operating activities, principal loan repayments from Moksha8, proceeds from the disposal of Medimetriks and net proceeds from marketable securities and bank loans.

Financial assets: As at September 30, 2023, financial assets were at $158,470, a decrease of $18,093 or 10%, as compared to December 31, 2022, driven mainly by a decrease of $18,170 due to negative mark-to-market adjustments from the decline in share prices of publicly-traded equities held by our strategic fund investments, strategic loan repayments of $12,454 from Moksha8, offset by the increase in the fair value of equity investments and derivatives of $12,520. Given the nature of the fund investments there could be significant fluctuations in the fair value of the underlying assets.

Bank Loans: As at September 30, 2023, bank loans were at $75,364, an increase of $5,292 or 8% as compared to December 31, 2022.

Product Updates

Fostamatinib: Knight submitted marketing authorization applications for fostamatinib, for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment, for regulatory approval in Mexico and Colombia.

Minjuvi ^® : Knight received regulatory approval in Brazil for Minjuvi ^® , in combination with lenalidomide followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL due to low-grade lymphoma, who are not eligible for autologous stem cell transplantation (ASCT). Subsequent to the quarter, the Company received pricing approval for Minjuvi ^® (tafasitamab) from the Drugs Market Regulation Chamber ("CMED"). As a result, Knight expects to launch Minjuvi ^® in Brazil in the second quarter of 2024.

Pemigatinib: Subsequent to the quarter, Knight submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Corporate Updates

Normal Course Issuer Bid

During the three month period ended September 30, 2023, the Company purchased 2,158,091 common shares at an average price of $4.55 for aggregate cash consideration of $9,833 of which $211 remains to be settled as at September 30, 2023. Subsequent to quarter-end up to October 31, 2023, the Company purchased an additional 676,775 common shares at an average purchase price of $4.53 for an aggregate cash consideration of $3,069.

Financial Outlook Update

Knight provides guidance on revenues ¹ on a non-GAAP basis. This is due to both the difficulty in predicting Argentinian inflation rates and its IAS 29 impact.

For fiscal 2023, Knight has updated its financial guidance on revenues and expects to generate between $325 million to $335 million in revenues an increase of $15 million on the lower end and $5 million on the upper end of the range. The adjusted EBITDA is expected to be approximately 18% of revenues. The increase in the financial outlook is primarily due to the Q4-23 MOH Order, as well as improvement in forecasted LATAM currencies against the Canadian dollar. The guidance is based on a number of assumptions, including but not limited to the following:

no revenues for business development transactions not completed as at November 9, 2023
discontinuation of certain distribution agreements
no interruptions in supply whether due to global supply chain disruptions or general manufacturing issues
no new generic entrants on our key pharmaceutical brands
no unforeseen changes to government mandated pricing regulations
successful commercial execution on product listing arrangements with HMOs, insurers, key accounts, and public payers
successful execution and uptake of newly launched products
no significant restrictions or economic shut down due to global pandemics
foreign currency exchange rates remaining within forecasted ranges

Should any of the assumptions differ, the financial outlook and the actual results may vary materially. Refer to the risks and assumptions referred to in the Forward-Looking Statements section of this news release for further details.

¹	_{Revenues excluding the impact of IAS 29 is a non-GAAP measure. Refer to the definitions in section "Non-GAAP measures" for additional details}

Conference Call Notice

Knight will host a conference call and audio webcast to discuss its third quarter ended September 30, 2023, today at 8:30 am ET. Knight cordially invites all interested parties to participate in this call.

Date: Thursday, November 9, 2023
Time: 8:30 a.m. ET
Telephone : Toll Free: 1-888-664-6383 or International 1-416-764-8650
Webcast: www.knighttx.com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay: An archived replay will be available for 30 days at www.knighttx.com

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedar.com .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2022 as filed on www.sedar.com . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

CONTACT INFORMATION:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T. +598.2626.2344
F: 514.481.4116
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

IMPACT OF HYPERINFLATION
[In thousands of Canadian dollars]

The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiaries used the Argentine Peso as their functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation. If the Company did not apply IAS 29, the effect on the Company's operating income would be as follows:

	Q3-23								YTD-23
	Reported under IFRS		Excluding impact of IAS 29 ¹		Variance				Reported under IFRS		Excluding impact of IAS 29 ¹		Variance
	Reported under IFRS		Excluding impact of IAS 29 ¹		$ ²		% ³		Reported under IFRS		Excluding impact of IAS 29 ¹		$ ²		% ³

Revenues	81,500		81,669		(169	)		—	254,002		254,736		(734	)		—
Cost of goods sold	41,318		39,548		(1,770	)	4	%	135,565		130,985		(4,580	)	3	%
Gross margin	40,182		42,121		(1,939	)	5	%	118,437		123,751		(5,314	)	4	%
Gross margin (%)	49	%	52	%					47	%	49	%

Expenses
Selling and marketing	11,924		11,937		13			—	35,463		35,635		172			—
General and administrative	11,080		11,009		(71	)	1	%	29,305		29,084		(221	)	1	%
Research and development	4,768		4,651		(117	)	3	%	13,291		13,376		85		1	%
Amortization of intangible assets	11,480		11,475		(5	)		—	33,925		33,789		(136	)		—
Operating income	930		3,049		(2,119	)	69	%	6,453		11,867		(5,414	)	46	%

¹	_{Financial results excluding the impact of hyperinflation is a non-GAAP measure. Refer to section "Non-GAAP measures" for additional details.}
²	_{A positive variance represents a positive impact on net income (loss) due to the application of IAS 29 and a negative variance represents a negative impact on net income (loss) due to the application of IAS 29.}
³	_{Percentage change is presented in absolute values.}

NON-GAAP MEASURES
[In thousands of Canadian dollars]

The Company discloses non-GAAP measures and ratios that do not have standardized meanings prescribed by IFRS. The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-GAAP financial measures and adjusted EBITDA per share ratio do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other companies.

The Company uses the following non-GAAP measures:

Revenues and Financial results excluding the impact of hyperinflation under IAS 29 : Revenues and financial results under IFRS are adjusted to remove the impact of hyperinflation under IAS 29. The impact of hyperinflation under IAS 29 is calculated by applying an appropriate general price index to express the effects of inflation. After applying the effects of translation, the statement of income is converted using the closing foreign exchange rate of the month.

Revenues and Financial results at constant currency : Revenues/financial results at constant currency are obtained by translating the prior period revenues/financial results from the functional currencies to CAD using the conversion rates in effect during the current period. Furthermore, with respect to Argentina, the Company excludes the impact of hyperinflation and translates the revenues/results at the average exchange rate in effect for each of the periods.

Revenues/financial results at constant currency allow revenues/financial results to be viewed without the impact of fluctuations in foreign currency exchange rates thereby facilitating the comparison of results period over period. The presentation of revenues/financial results under constant currency is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

Adjusted Gross Margin: Adjusted gross margin excludes the impact of IAS 29 and is adjusted to consider revenues and related cost of sales for Exelon ^® separately, rather than presenting as net profit transfer.

EBITDA: Operating income or loss adjusted to exclude amortization and impairment of intangible assets, depreciation, purchase price allocation accounting adjustments, and the impact of IAS 29 (accounting under hyperinflation) but to include costs related to leases.

Adjusted EBITDA: EBITDA adjusted for acquisition costs and non-recurring expenses.

Adjusted EBITDA per share: Adjusted EBITDA over number of common shares outstanding at the end of the respective period.

Adjustments include the following:

With the adoption of IFRS 16, the lease payments of Knight are not reflected in operating expenses. The IFRS 16 adjustment approximates the cash outflow related to leases of Knight.
Acquisition costs relate to costs incurred on legal, consulting and advisory fees for the acquisitions.
Other non-recurring expenses relate to expenses incurred by Knight that are not due to, and are not expected to occur in, the ordinary course of business.

For the three and nine-month period ended September 30, 2023, the Company calculated EBITDA and adjusted EBITDA as follows:

					Change								Change
	Q3-23		Q3-22		$ ¹		% ²		YTD-23		YTD-22		$ ¹		% ²
Operating income (loss)	930		(12,014	)	12,944		108	%	6,453		(9,994	)	16,447		165	%
Adjustments to operating income (loss):
Amortization of intangible assets	11,480		12,243		(763	)	6	%	33,925		34,586		(661	)	2	%
Impairment of intangible assets	—		2,080		(2,080	)	100	%	—		2,080		(2,080	)	100	%
Depreciation of property, plant and equipment and ROU assets	2,218		3,025		(807	)	27	%	5,014		7,841		(2,827	)	36	%
Lease costs (IFRS 16 adjustment)	(779	)	(625	)	(154	)	25	%	(2,146	)	(1,914	)	(232	)	12	%
Impact of IAS 29	1,663		4,300		(2,637	)	61	%	4,772		7,612		(2,840	)	37	%
EBITDA ³	15,512		9,009		6,503		72	%	48,018		40,211		7,807		19	%
Adjusted EBITDA ³	15,512		9,009		6,503		72	%	48,018		40,211		7,807		19	%

¹	_{A positive variance represents a positive impact to net income (loss) and a negative variance represents a negative impact to net income (loss).}
²	_{Percentage change is presented in absolute values.}
³	_{EBITDA and adjusted EBITDA are non-GAAP measures. Refer to the definitions in section "Non-GAAP measures" for additional details.}

The Company calculated adjusted EBITDA per share as follows:

	Q3-23	Q3-22	YTD-23	YTD-22
Adjusted EBITDA ¹	15,512	9,009	48,018	40,211
Adjusted EBITDA per share ¹	0.15	0.08	0.46	0.35
Number of common shares outstanding at period end (in thousands)	105,045	113,958	105,045	113,958

¹	_{Adjusted EBITDA and adjusted EBITDA per share are non-GAAP measures. Refer to the definitions in section "Non-GAAP measures" for additional details.}

INTERIM CONSOLIDATED BALANCE SHEETS
[In thousands of Canadian dollars]
[Unaudited]

As at	09-30-2023	12-31-2022
ASSETS
Current
Cash and cash equivalents	77,418	71,679
Marketable securities	65,040	85,826
Trade receivables	82,222	94,890
Other receivables	17,788	12,930
Inventories	112,447	92,489
Prepaids and deposits	2,567	1,704
Other current financial assets	40,487	33,716
Income taxes receivable	3,327	2,385
Total current assets	401,296	395,619

Marketable securities	11,357	15,169
Prepaids and deposits	1,069	4,355
Right-of-use assets	5,650	5,827
Property, plant and equipment	14,805	16,806
Intangible assets	311,201	338,780
Goodwill	85,883	82,274
Other financial assets	117,983	142,847
Deferred income tax assets	17,074	9,310
Other long-term receivables	44,831	43,849
	609,853	659,217
Total assets	1,011,149	1,054,836

INTERIM CONSOLIDATED BALANCE SHEETS (continued)
[In thousands of Canadian dollars]
[Unaudited]

As at	09-30-2023	12-31-2022

LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities	82,782	106,061
Lease liabilities	1,840	2,578
Other liabilities	1,515	5,793
Bank loans	25,684	17,674
Income taxes payable	1,882	2,274
Other balances payable	1,374	6,941
Total current liabilities	115,077	141,321

Accounts payable and accrued liabilities	220	2,669
Lease liabilities	4,813	5,050
Bank loans	49,680	52,398
Other balances payable	21,721	23,176
Deferred income tax liabilities	4,973	4,365
Total liabilities	196,484	228,979

Shareholders' equity
Share capital	560,500	599,055
Warrants	117	117
Contributed surplus	25,624	23,664
Accumulated other comprehensive income	54,689	41,266
Retained earnings	173,735	161,755
Total shareholders' equity	814,665	825,857
Total liabilities and shareholders' equity	1,011,149	1,054,836

INTERIM CONSOLIDATED STATEMENTS OF INCOME (LOSS)
[In thousands of Canadian dollars, except for share and per share amounts]
[Unaudited]

	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022

Revenues	81,500		72,281		254,002		211,908
Cost of goods sold	41,318		41,880		135,565		110,735
Gross margin	40,182		30,401		118,437		101,173

Expenses
Selling and marketing	11,924		13,456		35,463		34,072
General and administrative	11,080		10,416		29,305		29,814
Research and development	4,768		4,220		13,291		10,615
Amortization of intangible assets	11,480		12,243		33,925		34,586
Impairment of intangible assets	—		2,080		—		2,080
Operating income (loss)	930		(12,014	)	6,453		(9,994	)

Interest income on financial instruments measured at amortized cost	(2,024	)	(1,096	)	(6,218	)	(2,150	)
Other interest income	(1,031	)	(1,366	)	(3,276	)	(4,219	)
Interest expense	2,603		1,479		8,398		4,307
Other income	(1,907	)	(5,860	)	(2,123	)	(5,989	)
Net (gain) loss on financial instruments measured at fair value through profit or loss	(5,562	)	5,446		2,346		29,501
Foreign exchange (gain) loss	1,317		(10,787	)	6,162		(9,105	)
Gain on hyperinflation	(1,364	)	(681	)	(3,000	)	(1,514	)
Income (loss) before income taxes	8,898		851		4,164		(20,825	)

Income tax
Current	1,112		1,204		3,251		2,175
Deferred	(1,802	)	(1,944	)	(6,578	)	(8,296	)
Income tax recovery	(690	)	(740	)	(3,327	)	(6,121	)
Net income (loss) for the period	9,588		1,591		7,491		(14,704	)

Basic and diluted net income (loss) per share	0.09		0.01		0.07		(0.13	)
Weighted average number of common shares outstanding
Basic	106,250,793		114,466,484		108,728,924		115,569,933
Diluted	106,511,761		114,597,655		108,958,045		115,569,933

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
[In thousands of Canadian dollars]
[Unaudited]

	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022
OPERATING ACTIVITIES
Net income (loss) for the period	9,588		1,591		7,491		(14,704	)
Adjustments reconciling net income to operating cash flows:
Depreciation and amortization	13,698		15,268		38,939		42,427
Impairment of intangible assets	—		2,080		—		2,080
Net loss (gain) on financial instruments	(5,562	)	5,446		2,346		29,501
Unrealized foreign exchange (gain) loss	3,619		(8,104	)	1,557		(7,435	)
Other operating activities	1,058		(1,955	)	966		(5,058	)
	22,401		14,326		51,299		46,811
Changes in non-cash working capital and other items	(7,235	)	(2,534	)	(33,303	)	(8,449	)
Cash inflow from operating activities	15,166		11,792		17,996		38,362

INVESTING ACTIVITIES
Purchase of marketable securities	(52,118	)	(21,412	)	(237,668	)	(80,647	)
Proceeds on maturity of marketable securities	81,204		21,370		262,372		101,240
Investment in funds	(1,006	)	(2,847	)	(1,176	)	(3,300	)
Purchase of intangible assets	(60	)	(74	)	(7,727	)	(18,524	)
Other investing activities	7,736		(333	)	15,441		3,176
Cash inflow (outflow) from investing activities	35,756		(3,296	)	31,242		1,945

FINANCING ACTIVITIES
Repurchase of common shares through Normal Course Issuer Bid	(9,833	)	(4,463	)	(34,396	)	(21,385	)
Principal repayment of bank loans	(2,571	)	(56	)	(8,580	)	(5,447	)
Proceeds from bank loans	2,706		—		4,796		422
Other financing activities	(1,541	)	(1,070	)	(7,124	)	(4,319	)
Cash outflow from financing activities	(11,239	)	(5,589	)	(45,304	)	(30,729	)

Increase (decrease) in cash and cash equivalents during the period	39,683		2,907		3,934		9,578
Cash and cash equivalents, beginning of the period	37,844		93,119		71,679		85,963
Net foreign exchange difference	(109	)	5,796		1,805		6,281
Cash and cash equivalents, end of the period	77,418		101,822		77,418		101,822

Cash and cash equivalents					77,418		101,822
Marketable securities					76,397		43,320
Total cash, cash equivalents and marketable securities					153,815		145,142

News Provided by GlobeNewswire via QuoteMedia

Knight Therapeutics GUD:CA Medical Device Investing

GUD:CA

Artificial Intelligence Reshaping Healthcare Industry with Unimaginable Potential

FN Media Group News Commentary - The Healthcare Artificial Intelligence (AI) market exhibits a high degree of innovation, characterized by ongoing advancements in technology. Rapid developments in ML, deep learning, NLP, and computer vision are driving the evolution of AI-powered healthcare solutions. One primary factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy, and better patient outcomes. According to a March 2024 Microsoft-IDC study, 79% of healthcare organizations are presently utilizing AI technology. In addition, the return on investment (ROI) is realized within 14 months, generating USD 3.20 for every USD 1 invested in artificial intelligence (AI). AI technologies hold transformative potential in various areas including medical imaging analysis, predictive analytics, personalized treatment planning, and drug discovery, potentially transforming conventional healthcare practices. A report from Grand View Research said the global AI in healthcare market size, which was estimated at USD 19.27 billion in 2023, is expected to grow at a CAGR of 38.5% from 2024 to 2030. The report said: "Mergers & acquisitions (M&As) play a significant role in shaping the healthcare AI market landscape. Companies [that] engage in M&A activities to expand their AI software and services increase their market reach or acquire specialized technology and expertise. End-users are becoming increasingly aware of the potential benefits of AI in improving patient care, operational efficiency, and healthcare outcomes. Education initiatives and industry events helped raise awareness about the capabilities and applications of AI in healthcare." A.I. companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Teladoc Health, Inc. (NYSE: TDOC), Tempus AI, Inc. (NASDAQ: TEM), Medtronic plc (NYSE: MDT), Clover Health Investments, Corp. (NASDAQ: CLOV).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic receives FDA clearance for new InPen app, paving the way for its Smart MDI system launch with Simplera CGM

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM). The company's Smart MDI system combines its InPen™ smart insulin pen with its newest Simplera™ CGM — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Announces Health Canada Approval for JORNAY PM to Treat Attention-Deficit Hyperactivity Disorder

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM ™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children.

JORNAY PM ™ is the first and only evening-dosed methylphenidate product commercially available in Canada to treat ADHD in patients from 6 to 12 years of age. JORNAY PM ™ consists of microbeads with a delayed-release layer and an extended-release layer. The first layer delays the release of the active ingredient until morning while the extended-release layer controls the release of the active ingredient starting in the morning and continuing throughout the day. This unique formulation provides a pharmacokinetic profile that allows ADHD symptom control from the time patients wake up until the evening.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Gold Investing

Contacts:
Janet Cho	Ryan Weispfenning
Public Relations	Investor Relations
+1-818-403-7028	+1-763-505-4626

MEDTRONIC PLC WORLD WIDE REVENUE ⁽¹⁾ (Unaudited)

	SECOND QUARTER							YEAR-TO-DATE
	REPORTED				ORGANIC			REPORTED				ORGANIC
(in millions)	FY25	FY24	Growth	Currency Impact ⁽³⁾	Adjusted FY25 ⁽⁴⁾	Adjusted FY24 ⁽⁴⁾	Growth	FY25	FY24	Growth	Currency Impact ⁽³⁾	Adjusted FY25 ⁽⁵⁾	Adjusted FY24 ⁽⁵⁾	Growth
Cardiovascular	$ 3,102	$ 2,923	6.1 %	$ 16	$ 3,086	$ 2,923	5.6 %	$ 6,108	$ 5,773	5.8 %	$ (23)	$ 6,132	$ 5,773	6.2 %
Cardiac Rhythm & Heart Failure	1,578	1,492	5.8	11	1,567	1,492	5.0	3,114	2,938	6.0	(8)	3,122	2,938	6.2
Structural Heart & Aortic	881	819	7.6	4	877	819	7.1	1,736	1,633	6.3	(8)	1,744	1,633	6.8
Coronary & Peripheral Vascular	643	613	4.9	1	642	613	4.8	1,259	1,202	4.7	(7)	1,266	1,202	5.3
Neuroscience	2,451	2,288	7.1	10	2,441	2,288	6.7	4,768	4,506	5.8	(8)	4,776	4,506	6.0
Cranial & Spinal Technologies	1,234	1,157	6.7	3	1,231	1,157	6.4	2,382	2,260	5.4	(6)	2,387	2,260	5.6
Specialty Therapies	737	705	4.6	5	732	705	3.9	1,450	1,400	3.5	(2)	1,452	1,400	3.7
Neuromodulation	480	426	12.6	2	478	426	12.1	937	846	10.8	(1)	938	846	10.9
Medical Surgical	2,128	2,103	1.2	10	2,117	2,103	0.7	4,123	4,107	0.4	(18)	4,142	4,107	0.8
Surgical & Endoscopy	1,649	1,641	0.5	9	1,641	1,641	—	3,193	3,187	0.2	(13)	3,207	3,187	0.6
Acute Care & Monitoring	478	462	3.6	1	477	462	3.3	930	921	1.0	(5)	935	921	1.6
Diabetes	686	610	12.4	9	678	610	11.0	1,333	1,189	12.1	5	1,329	1,189	11.8
Total Reportable Segments	8,366	7,923	5.6	45	8,322	7,923	5.0	16,333	15,575	4.9	(46)	16,379	15,575	5.2
Other ⁽²⁾	37	61	(38.9)	—	—	—	—	(15)	111	(113.5)	(2)	—	—	—
TOTAL	$ 8,403	$ 7,984	5.3 %	$ 45	$ 8,322	$ 7,923	5.0 %	$ 16,318	$ 15,686	4.0 %	$ (48)	$ 16,379	$ 15,575	5.2 %


(1)	The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(2)	Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.
(3)	The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.
(4)	The three months ended October 25, 2024 includes $82 million of revenue adjustments related to $37 million of inorganic revenue for the transition activity noted in (2) and $45 million of favorable currency impact on the remaining segments. The three months ended October 27, 2023 excludes $61 million of inorganic revenue related to the transition activity noted in (2).
(5)	The six months ended October 25, 2024 excludes $61 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $75 million of inorganic revenue related to the transition activity noted in (2), and $46 million of unfavorable currency impact on the remaining segments. The six months ended October 27, 2023 excludes $111 million of inorganic revenue related to the transition activity noted in (2).

MEDTRONIC PLC U.S. ⁽¹⁾⁽²⁾ REVENUE (Unaudited)

	SECOND QUARTER						YEAR-TO-DATE
	REPORTED			ORGANIC			REPORTED			ORGANIC
(in millions)	FY25	FY24	Growth	Adjusted FY25	Adjusted FY24	Growth	FY25	FY24	Growth	Adjusted FY25	Adjusted FY24	Growth
Cardiovascular	$ 1,434	$ 1,427	0.5 %	$ 1,434	$ 1,427	0.5 %	$ 2,836	$ 2,776	2.2 %	$ 2,836	$ 2,776	2.2 %
Cardiac Rhythm & Heart Failure	768	782	(1.8)	768	782	(1.8)	1,534	1,502	2.1	1,534	1,502	2.1
Structural Heart & Aortic	388	367	5.7	388	367	5.7	757	724	4.5	757	724	4.5
Coronary & Peripheral Vascular	278	278	0.1	278	278	0.1	546	550	(0.8)	546	550	(0.8)
Neuroscience	1,677	1,560	7.5	1,677	1,560	7.5	3,242	3,057	6.0	3,242	3,057	6.0
Cranial & Spinal Technologies	926	863	7.2	926	863	7.2	1,781	1,685	5.7	1,781	1,685	5.7
Specialty Therapies	418	403	3.6	418	403	3.6	816	795	2.6	816	795	2.6
Neuromodulation	333	293	13.7	333	293	13.7	645	577	11.8	645	577	11.8
Medical Surgical	944	948	(0.4)	944	948	(0.4)	1,825	1,815	0.5	1,825	1,815	0.5
Surgical & Endoscopy	675	688	(1.9)	675	688	(1.9)	1,304	1,308	(0.2)	1,304	1,308	(0.2)
Acute Care & Monitoring	269	260	3.6	269	260	3.6	521	508	2.6	521	508	2.6
Diabetes	232	217	6.9	232	217	6.9	447	405	10.4	447	405	10.4
Total Reportable Segments	4,286	4,151	3.3	4,286	4,151	3.3	8,350	8,054	3.7	8,350	8,054	3.7
Other ⁽³⁾	18	23	(22.2)	—	—	—	37	45	(19.0)	—	—	—
TOTAL	$ 4,304	$ 4,175	3.1 %	$ 4,286	$ 4,151	3.3 %	$ 8,387	$ 8,099	3.6 %	$ 8,350	$ 8,054	3.7 %

MEDTRONIC PLC INTERNATIONAL REVENUE ⁽¹⁾ (Unaudited)

	SECOND QUARTER							YEAR-TO-DATE
	REPORTED				ORGANIC			REPORTED				ORGANIC
(in millions)	FY25	FY24	Growth	Currency Impact ⁽³⁾	Adjusted FY25 ⁽⁴⁾	Adjusted FY24 ⁽⁴⁾	Growth	FY25	FY24	Growth	Currency Impact ⁽³⁾	Adjusted FY25 ⁽⁵⁾	Adjusted FY24 ⁽⁵⁾	Growth
Cardiovascular	$ 1,668	$ 1,496	11.5 %	$ 16	$ 1,652	$ 1,496	10.4 %	$ 3,272	$ 2,996	9.2 %	$ (23)	$ 3,295	$ 2,996	10.0 %
Cardiac Rhythm & Heart Failure	811	710	14.2	11	799	710	12.6	1,580	1,436	10.0	(8)	1,588	1,436	10.6
Structural Heart & Aortic	492	451	9.1	4	488	451	8.3	980	909	7.8	(8)	988	909	8.7
Coronary & Peripheral Vascular	365	335	8.9	1	364	335	8.7	713	652	9.3	(7)	720	652	10.4
Neuroscience	774	728	6.3	10	764	728	5.0	1,526	1,449	5.3	(8)	1,535	1,449	5.9
Cranial & Spinal Technologies	308	293	5.0	3	305	293	3.9	600	576	4.2	(6)	606	576	5.2
Specialty Therapies	319	302	5.8	5	315	302	4.3	634	605	4.8	(2)	636	605	5.1
Neuromodulation	146	133	10.4	2	144	133	8.8	292	269	8.8	(1)	293	269	9.1
Medical Surgical	1,183	1,155	2.5	10	1,173	1,155	1.6	2,298	2,292	0.3	(18)	2,317	2,292	1.1
Surgical & Endoscopy	974	953	2.3	9	966	953	1.4	1,889	1,879	0.5	(13)	1,902	1,879	1.2
Acute Care & Monitoring	209	202	3.5	1	208	202	2.8	409	413	(0.9)	(5)	414	413	0.4
Diabetes	455	394	15.5	9	446	394	13.2	886	784	13.1	5	882	784	12.5
Total Reportable Segments	4,080	3,772	8.2	45	4,035	3,772	7.0	7,983	7,521	6.1	(46)	8,028	7,521	6.7
Other ⁽²⁾	19	37	(49.4)	—	—	—	—	(51)	66	(178.3)	(2)	—	—	—
TOTAL	$ 4,099	$ 3,809	7.6 %	$ 45	$ 4,035	$ 3,772	7.0 %	$ 7,931	$ 7,587	4.5 %	$ (48)	$ 8,028	$ 7,521	6.7 %


(1)	U.S. includes the United States and U.S. territories.
(2)	The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(3)	Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested.

MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

	Three months ended		Six months ended
(in millions, except per share data)	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Net sales	$ 8,403	$ 7,984	$ 16,318	$ 15,686
Costs and expenses:
Cost of products sold, excluding amortization of intangible assets	2,946	2,761	5,707	5,390
Research and development expense	697	698	1,373	1,365
Selling, general, and administrative expense	2,757	2,686	5,412	5,299
Amortization of intangible assets	413	425	827	855
Restructuring charges, net	30	40	77	94
Certain litigation charges, net	—	65	81	105
Other operating income, net	(34)	(31)	(33)	(30)
Operating profit	1,595	1,340	2,873	2,608
Other non-operating income, net	(173)	(154)	(330)	(230)
Interest expense, net	209	180	376	329
Income before income taxes	1,559	1,313	2,827	2,510
Income tax provision	281	402	500	802
Net income	1,278	911	2,327	1,708
Net income attributable to noncontrolling interests	(9)	(2)	(15)	(8)
Net income attributable to Medtronic	$ 1,270	$ 909	$ 2,312	$ 1,700
Basic earnings per share	$ 0.99	$ 0.68	$ 1.79	$ 1.28
Diluted earnings per share	$ 0.99	$ 0.68	$ 1.79	$ 1.28
Basic weighted average shares outstanding	1,282.4	1,330.2	1,288.6	1,330.3

Diluted weighted average shares outstanding	1,286.9	1,331.9	1,292.5	1,332.8

MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS ⁽¹⁾ (Unaudited)

	Three months ended October 25, 2024
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income Before Income Taxes	Net Income attributable to Medtronic	Diluted EPS	Effective Tax Rate
GAAP	$ 8,403	$ 2,946	64.9 %	$ 1,595	19.0 %	$ 1,559	$ 1,270	$ 0.99	18.0 %
Non-GAAP Adjustments:
Amortization of intangible assets	—	—	—	413	4.9	413	338	0.26	18.2
Restructuring and associated costs ⁽²⁾	—	(11)	0.1	46	0.5	46	37	0.03	19.6
Acquisition and divestiture-related items ⁽³⁾	—	(5)	0.1	(25)	(0.3)	(25)	(30)	(0.02)	(20.0)
(Gain)/loss on minority investments ⁽⁴⁾	—	—	—	—	—	(10)	(21)	(0.02)	(100.0)
Medical device regulations ⁽⁵⁾	—	(9)	0.1	12	0.1	12	10	0.01	16.7
Certain tax adjustments, net	—	—	—	—	—	—	16	0.01	—
Non-GAAP	$ 8,403	$ 2,921	65.2 %	$ 2,041	24.3 %	$ 1,995	$ 1,620	$ 1.26	18.3 %
Currency impact	(45)	(103)	1.1	145	1.9			0.09
Currency Adjusted	$ 8,358	$ 2,818	66.3 %	$ 2,186	26.2 %			$ 1.35

	Three months ended October 27, 2023
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income Before Income Taxes	Net Income attributable to Medtronic	Diluted EPS	Effective Tax Rate
GAAP	$ 7,984	$ 2,761	65.4 %	$ 1,340	16.8 %	$ 1,313	$ 909	$ 0.68	30.6 %
Non-GAAP Adjustments:
Amortization of intangible assets	—	—	—	425	5.3	425	360	0.27	15.3
Restructuring and associated costs ⁽²⁾	—	(15)	0.2	91	1.1	91	76	0.06	17.6
Acquisition and divestiture-related items ⁽³⁾	—	(6)	0.1	58	0.7	58	51	0.04	12.1
Certain litigation charges, net	—	—	—	65	0.8	65	50	0.04	23.1
(Gain)/loss on minority investments ⁽⁴⁾	—	—	—	—	—	25	21	0.02	20.0
Medical device regulations ⁽⁵⁾	—	(21)	0.3	30	0.4	30	24	0.02	20.0
Certain tax adjustments, net ⁽⁶⁾	—	—	—	—	—	—	176	0.13	—
Non-GAAP	$ 7,984	$ 2,720	65.9 %	$ 2,009	25.2 %	$ 2,008	$ 1,667	$ 1.25	16.9 %


See description of non-GAAP financial measures contained in the press release dated November 19, 2024.
(1)	The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.
(2)	Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs.
(3)	The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The three months ended October 25, 2024, also include gains related to certain business or asset sales.
(4)	We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(5)	The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.
(6)	The charge primarily relates to the establishment of a valuation allowance against certain net operating losses.

MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS ⁽¹⁾ (Unaudited)

	Six months ended October 25, 2024
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income Before Income Taxes	Net Income attributable to Medtronic	Diluted EPS	Effective Tax Rate
GAAP	$ 16,318	$ 5,707	65.0 %	$ 2,873	17.6 %	$ 2,827	$ 2,312	$ 1.79	17.7 %
Non-GAAP Adjustments:
Amortization of intangible assets	—	—	—	827	4.9	827	678	0.52	18.0
Restructuring and associated costs ⁽²⁾	—	(20)	0.1	108	0.6	108	87	0.07	19.4
Acquisition and divestiture-related items ⁽³⁾	—	(16)	0.1	(13)	(0.1)	(13)	(19)	(0.01)	(46.2)
Certain litigation charges, net	—	—	—	81	0.5	81	68	0.05	16.0
(Gain)/loss on minority investments ⁽⁴⁾	—	—	—	—	—	(27)	(38)	(0.03)	(37.0)
Medical device regulations ⁽⁵⁾	—	(20)	0.1	27	0.2	27	22	0.02	18.5
Other ⁽⁶⁾	90	—	0.4	90	0.5	90	70	0.05	22.2
Certain tax adjustments, net	—	—	—	—	—	—	33	0.03	—
Non-GAAP	$ 16,408	$ 5,651	65.6 %	$ 3,993	24.3 %	$ 3,921	$ 3,213	$ 2.49	17.7 %
Currency impact	46	(134)	0.9	246	1.5			0.16
Currency Adjusted	$ 16,454	$ 5,517	66.5 %	$ 4,239	25.8 %			$ 2.65

	Six months ended October 27, 2023
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income Before Income Taxes	Net Income attributable to Medtronic	Diluted EPS	Effective Tax Rate
GAAP	$ 15,686	$ 5,390	65.6 %	$ 2,608	16.6 %	$ 2,510	$ 1,700	$ 1.28	32.0 %
Non-GAAP Adjustments:
Amortization of intangible assets	—	—	—	855	5.5	855	724	0.54	15.2
Restructuring and associated costs ⁽²⁾	—	(30)	0.2	182	1.2	182	152	0.11	16.5
Acquisition and divestiture-related items ⁽³⁾	—	(12)	0.1	107	0.7	107	97	0.07	9.3
Certain litigation charges, net	—	—	—	105	0.7	105	81	0.06	22.9
(Gain)/loss on minority investments ⁽⁴⁾	—	—	—	—	—	89	85	0.06	5.6
Medical device regulations ⁽⁵⁾	—	(42)	0.3	62	0.4	62	49	0.04	21.0
Certain tax adjustments, net ⁽⁷⁾	—	—	—	—	—	—	375	0.28	—
Non-GAAP	$ 15,686	$ 5,306	66.2 %	$ 3,919	25.0 %	$ 3,910	$ 3,262	$ 2.45	16.4 %


See description of non-GAAP financial measures contained in the press release dated November 19, 2024.
(1)	The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
(2)	Free cash flow represents operating cash flows less property, plant, and equipment additions.

MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited)

(in millions)	October 25, 2024	April 26, 2024
ASSETS
Current assets:
Cash and cash equivalents	$ 1,394	$ 1,284
Investments	6,595	6,721
Accounts receivable, less allowances and credit losses of $195 and $173, respectively	6,260	6,128
Inventories	5,479	5,217
Other current assets	2,710	2,584
Total current assets	22,438	21,935
Property, plant, and equipment, net	6,438	6,131
Goodwill	41,161	40,986
Other intangible assets, net	12,423	13,225
Tax assets	3,572	3,657
Other assets	4,009	4,047
Total assets	$ 90,042	$ 89,981
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations	$ 3,719	$ 1,092
Accounts payable	2,376	2,410
Accrued compensation	1,893	2,375
Accrued income taxes	947	1,330
Other accrued expenses	3,260	3,582
Total current liabilities	12,195	10,789
Long-term debt	24,607	23,932
Accrued compensation and retirement benefits	1,084	1,101
Accrued income taxes	1,432	1,859
Deferred tax liabilities	473	515
Other liabilities	1,534	1,365
Total liabilities	41,326	39,561
Commitments and contingencies
Shareholders' equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,282,553,150 and 1,311,337,531 shares issued and outstanding, respectively	—	—
Additional paid-in capital	20,824	23,129
Retained earnings	30,919	30,403
Accumulated other comprehensive loss	(3,250)	(3,318)
Total shareholders' equity	48,494	50,214
Noncontrolling interests	222	206
Total equity	48,716	50,420
Total liabilities and equity	$ 90,042	$ 89,981

Contacts:

Erika Winkels	Ryan Weispfenning
Public Relations	Investor Relations
+1-763-526-8478	+1-763-505-4626

Knight Therapeutics Reports Third Quarter 2023 Results

Latest News

Latest Press Releases

Related News

TOP STOCKS